Skip to main content

Table 2 The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic regimens

From: Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study

 

Total

2002–2005a

2006–2009

2010–2013

p for trend

Penicillin-gentamicin

 Total

6.1

4.4

6.1

7.5

0.011

 Community acquired

4.3

2.2

5.7

5.0

0.22

 Health care-associated

6.7

7.4

5.8

7.2

0.16

 Hospital acquired

10.2

4.4

8.6

16.5

0.023

 p for trend

0.006

0.058

0.46

0.003

 

Penicillin-gentamicin-metronidazole

 Total

3.5

1.9

3.0

5.2

<0.001

 Community acquired

1.4

0.3

1.8

2.1

0.28

 Health care-associated

4.8

4.6

3.2

6.3

0.045

 Hospital acquired

6.9

2.2

6.2

11.7

0.026

 p for trend

<0.001

0.007

0.15

0.001

 

Piperacillin/tazobactam

 Total (n = 1413)

7.6

 

7.4

7.7

0.25

 Community acquired (n = 617)

3.6

 

2.9

4.2

0.27

 Health care-associated (n = 612)

8.8

 

9.4

8.4

0.31

 Hospital acquired (n = 184)

8.8

 

9.4

17.0

0.31

 p for trend

<0.001

 

<0.001

<0.001

 

Piperacillin/tazobactam-gentamicin

 Total (n = 1413)

3.0

 

2.4

3.6

0.21

 Community acquired (n = 617)

1.0

 

0.7

1.2

0.69

 Health care-associated (n = 612)

3.3

 

3.2

3.3

0.98

 Hospital acquired (n = 184)

9.2

 

4.9

12.6

0.12

 p for trend

<0.001

 

0.037

<0.001

 

Piperacillin/tazobactam-gentamicin-metronidazole

 Total (n = 1413)

2.6

 

1.7

3.4

0.065

 Community acquired (n = 617)

0.5

 

0.0

0.9

0.26

 Health care-associated (n = 612)

2.9

 

2.5

3.3

0.64

 Hospital acquired (n = 184)

8.7

 

4.9

11.7

0.12

 p for trend

<0.001

 

0.004

<0.001

 

Imipenem

 Community acquired

1.1

1.6

0.7

0.9

0.59

 Health care-associated

6.5

9.1

5.8

5.7

0.39

 Hospital acquired

10.6

11.1

7.4

12.6

0.14

 p for trend

<0.001

<0.001

0.001

<0.001

 

Cefotaxime

 Total

17.8

17.5

18.7

17.3

0.68

 Community acquired

10.8

11.0

11.4

10.1

0.69

 Health care-associated

21.3

25.1

22.7

18.2

0.18

 Hospital acquired

31.4

25.6

29.6

37.9

0.31

 p for trend

<0.001

<0.001

<0.001

<0.001

 

Ceftazidime

 Total

27.8

29.0

24.8

29.4

0.25

 Community acquired

18.5

20.2

15.4

19.6

0.42

 Health care-associated

31.3

36.0

28.2

31.3

0.37

 Hospital acquired

49.6

46.7

45.7

55.3

0.46

 p for trend

<0.001

<0.001

<0.001

<0.001

 
  1. aPiperacillin/tazobactam was not adopted in the first time period
  2. The BSIs are stratified by place of acquisition and by time period (the total number in each cell is shown under the heading Place of acquisition in Table 1)